10x Genomics’s (NASDAQ:TXG) Q2 CY2026: Strong Sales, Full
10x Genomics (NASDAQ:TXG) reported Q2 CY2026 results. Revenue fell 12.6% year on year to $151 million but beat expectations by 3.1%. Full-year revenue guidance was $620 million at the midpoint, about 1% above estimates. GAAP EPS was -$0.14, 43.3% worse than consensus. The stock fell 3.4% to $44.05 after the report.
How this was made
The 30-second read
Why it matters
Q2 CY2026 results beat revenue and EPS expectations, and full-year revenue guidance is slightly above estimates, but the company still shows YoY revenue contraction and negative GAAP earnings with negative adjusted operating margin.
Market read
Traders can reassess TXG’s near-term fundamentals using the specific Q2 beat, full-year revenue midpoint guidance, and the immediate post-report stock drop.
What to watch
Consumables growth averaged 10.3% YoY over two years, which may support longer-term recurring revenue even as total revenue declines.
Background
10x Genomics develops instruments, consumables, and software for single-cell resolution and spatial biology research.
Ticker impact
10x Genomics reported Q2 CY2026 revenue of $151M, down 12.6% YoY but above expectations, and guided full-year revenue to $620M midpoint.
Near-term volatility likely, with downside risk if investors focus on the YoY revenue decline and weak profitability despite the beat.
The article provides concrete Q2 results (revenue, GAAP EPS, guidance) and notes the stock fell 3.4% immediately after reporting, implying the market weighed growth deceleration and losses more than the beat.
Market effects
Signals ongoing demand for single-cell/spatial genomics tools but highlights profitability pressure typical for unprofitable biotech instrument platforms.
Limited, primarily affects US biotech/synthetic biology instrument sentiment.
Low, no international regulatory or supply-chain developments mentioned.
Counterpoint
The revenue beat plus strong early order flow tied to Atera could indicate a near-term inflection that the market is underpricing.
Key entities
- company10x Genomics
Reported Q2 CY2026 revenue and GAAP EPS, provided full-year revenue guidance, and cited customer response to Atera.
- productAtera
Referenced as driving extraordinary customer response and strong early order flow during the quarter.
